-
Australia
-
Austria
-
Belgium
-
Brazil
-
Canada
-
China
-
Czech Republic
-
Denmark
-
Finland
-
France
-
Germany
-
Greece
-
Hong Kong
-
Hungary
-
Iceland
-
India
-
Ireland
-
Israel
-
Italy
-
Japan
-
Korea
-
Luxembourg
-
Malaysia
-
Netherlands
-
New Zealand
-
Norway
-
Poland
-
Qatar
-
Romania
-
Saudi Arabia
-
Singapore
-
Spain
-
Sweden
-
Switzerland
-
Taiwan
-
Turkey
-
United Kingdom
-
United States
Biosimilar Antibodies
| Cat.No. | Product Name | Information | Isotype |
|---|---|---|---|
| A2311 | Anti-TrkA / NTRK1 | Anti-TrkA / NTRK1 is a non-conjugated, rabbit-derived monoclonal antibody targeting TrkA. MW : 145.5 KD. | Human IgG1 |
| A2312 | Vorsetuzumab (Anti-TNFSF7 / CD27L / CD70) | Vorsetuzumab (Anti-TNFSF7 / CD27L / CD70) is a humanized monoclonal antibody that specifically recognizes and binds to CD70 molecular. Vorsetuzumab enhances macrophage-related phagocytosis of renal carcinoma cells and shows inhibitory efficacy against Burkitt’s lymphoma. MW : 150 kDa. | Human IgG1 |
| A2568 | Mogamulizumab (Anti-CCR4 / CD194) | Mogamulizumab (Anti-CCR4 / CD194) is a defucosylated humanized recombinant monoclonal antibody targeting CCR4. Mogamulizumab can eliminate tumor cells by antibody-dependent cellular cytotoxicity (ADCC). Mogamulizumab can be used in the research of cancers, adult T-cell leukemia/lymphoma (ATLL), cutaneous T-cell lymphoma (CTCL). MW:145.5 KD. | Human IgG1 |
| A2313 | Dapirolizumab (Anti-TNFSF5 / CD40L / CD154) | Dapirolizumab (Anti-TNFSF5 / CD40L / CD154) is a humanized immunoglobulin monoclonal antibody that targets TNFSF5. MW : 150 kDa. | Human IgG1 |
| A2314 | Oxelumab (Anti-TNFSF4 / OX40L / CD252) | Oxelumab (Anti-TNFSF4 / OX40L / CD252) is a human monoclonal antibody against the OX40 ligand (OX40L) with the potential to be used for asthma research. MW : 145.5 kDa. | Human IgG1 |
| A2571 | Anti-CCL5 / RANTES | Anti-CCL5 / RANTES (NI-0701) is a antibody tageting CCL5. MW:145.5 KD. | Human IgG2SA |
| A2572 | Anti-CCL20 | Anti-CCL20 (GSK3050002) is a humanized IgG1κ antibody with high binding affinity to the human chemokine, CCL20. MW:145.5 KD. | Human IgG4SP |
| A2317 | Sibeprenlimab (Anti-TNFSF13 / APRIL / CD256) | Sibeprenlimab (Anti-TNFSF13 / APRIL / CD256) is a fully humanized IgG2κ monoclonal antibody that targets the B-cell growth factor APRIL (TNFSF13), with the potential to treat IgA nephropathy (IgAN). MW : 145.5 KD. | Human IgG2SA |
| A2318 | Anti-TNFSF12 / TWEAK | Anti-TNFSF12 / TWEAK is a humanized monoclonal antibody directed against the apoptotic ligand TNF-like weak inducer of apoptosis (TWEAK) with potential antineoplastic activity. It is used to treat renal interstitial fibrosis. MW : 145.5 KD. | Human IgG1 |
| A2574 | Nimacimab (Anti-CB1 / CNR1) | Nimacimab (Anti-CB1/CNR1) is a negative-allosteric modulating monoclonal antibody targeting CB1 receptor. Nimacimab can be used for research of metabolic diseases. MW:145.5 KD. | Human IgG4SP |
| A2575 | Anti-CB1 / CNR1 | Anti-CB1 / CNR1 (GFB-024) is a recombinant humanised monoclonal antinody that is used for targeting of CB1 receptor. MW:145.5 KD. | Human IgG1 |
| A2320 | Pateclizumab (Anti-TNFSF1 / TNFb) | Pateclizumab (Anti-TNFSF1 / TNFb) is a humanized monoclonal antibody that blocks and depletes anti-lymphotoxin α (LTα). It has a great potential for the treatment of rheumatoid arthritis (RA). MW : 145.5 KD. | Human IgG1 |
| A2576 | Erenumab (Anti-CALCRL / CGRPR) | Erenumab (Anti-CALCRL/CGRPR) is a fully human monoclonal antibody targeting CGRP receptor (calcitonin gene–related peptide receptor). Erenumab can be used for the prevention of episodic migraine. MW:145.5 KD. | Human IgG2SA |
| A2321 | Urelumab (Anti-TNFRSF9 / 4-1BB / CD137) | Urelumab (Anti-TNFRSF9 / 4-1BB / CD137) is a fully human agonistic monoclonal antibody targeting the CD137 receptor with potential immunostimulatory and antineoplastic activities. MW : 146.5 KD. | Human IgG4SP |
| A2577 | Galcanezumab (Anti-CALCA / CGRP) | Galcanezumab (Anti-CALCA/CGRP) is a humanized IgG4 monoclonal antibody targeting the CGRP ligand. Galcanezumab can be used for migraine or cluster headaches research. MW:145.5 KD. | Human IgG4SP |
| A2322 | Brentuximab (Anti-TNFRSF8 / CD30) | Brentuximab (Anti-TNFRSF8 / CD30) is a chimeric monoclonal antibody targeting anti-CD30 with antineoplastic activity. It has the potential to alter the disease course of non-MF/SS CTCLs. MW : 145.38 KD. | Human IgG1 |
| A2578 | Girentuximab (Anti-CA9 / Carbonic anhydrase 9) | Girentuximab (Anti-CA9 / Carbonic anhydrase 9) is a chimeric monoclonal antibody that targets and binds to Carbonic Anhydrase IX (CAIX) / Carbonic Anhydrase 9 (CA9), a cell surface glycoprotein ubiquitously expressed in clear cell renal cell carcinoma (ccRCC). MW:145.5 KD. | Human IgG1 |
| A2323 | Varlilumab (Anti-TNFRSF7 / CD27) | Varlilumab (Anti-TNFRSF7 / CD27) is a human monoclonal antibody with activity against the CD27 receptor. It exhibits potential immunostimulating and antineoplastic activity. MW : 150 KD. | Human IgG1 |
| A2579 | Sutimlimab (Anti-C1s) | Sutimlimab (Anti-C1s) is a humanized monoclonal antibody that targets the C1s protein in the classical complement pathway. It can be used for the research of cold agglutinin disease. C1s is a serine protease which cleaves C4 and C2 to form the C3 convertase. MW:145.5 KD. | Human IgG4SP |
| A2324 | Iscalimab (Anti-TNFRSF5 / CD40) | Iscalimab (Anti-TNFRSF5 / CD40) is a non-depleting IGg1 monoclonal antibody targeting CD40. Iscalimab can be used for research on Graves' hyperthyroidism and autoimmune diseases. MW : 145.5 KD. | Human IgG1 |
Products are for research use only. Not for human use. We do not sell to patients.
©Copyright 2013 Selleck Chemicals. All Rights Reserved.